	US 12,252,542 B2
	Anti-CD137 antibodies and method of treating colorectal cancer using them
Xin Zhang, Suzhou (CN); Jianjian Peng, Suzhou (CN); Kai Fu, Suzhou (CN); Hui Ma, Suzhou (CN); Xiaolong Pan, Suzhou (CN); Shilong Fu, Suzhou (CN); Shuli Ma, Suzhou (CN); and Jian Ding, Suzhou (CN)
Assigned to Shihuida Pharmaceutical Group (Jilin) Co., Ltd., Baishan (CN)
Appl. No. 17/285,760
Filed by SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD., Baishan (CN)
PCT Filed Sep. 12, 2019, PCT No. PCT/CN2019/105537 § 371(c)(1), (2) Date Apr. 15, 2021, PCT Pub. No. WO2020/078149, PCT Pub. Date Apr. 23, 2020.
Claims priority of application No. PCT/CN2018/111086 (WO), filed on Oct. 19, 2018.
Prior Publication US 2021/0380708 A1, Dec. 9, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/74 (2013.01)]

20 Claims

1. An antibody specifically binding CD137 or an antigen binding fragment thereof, comprising a light chain variable region VL and a heavy chain variable region VH, wherein compared to a sequence as shown in SEQ ID NO: 103, the VL comprises one or more VL amino acid mutations, and the VL amino acid mutation occurs at one or more positions selected from a group consisting of: V3, A10, K44, D71 and V77;

wherein compared to a sequence as shown in SEQ ID NO: 127, the VH comprises one or more VH amino acid mutations, and the VH amino acid mutation occurs at one or more positions selected from a group consisting of: Q13, N78, H84, D86, A90 and F97.

20. A method of treating cancer, the method comprising:

administering an effective amount of the antibody or fragment of claim 1 to a subject in need thereof,

wherein the cancer is colorectal cancer.